Pesquisar
PDS Biotechnology Corp
PDSBAdicionar à lista de desejos
1.020USD
-0.045-4.23%
Fechamento 10-08 16:00（ET）
57.04MValor de mercado
PerdaP/L TTM
Após o expediente 18:49 (ET)1.020USD-0.020-1.92%
Após o expediente 18:49 (ET)Sobre o PDS Biotechnology Corp Empresa
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
PDS Biotechnology Corp Perfil
Código da empresaPDSB
Nome da EmpresaPDS Biotechnology Corp
Data de listagemOct 01, 2015
CEOBedu-Addo (Frank)
Número de funcionários24
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 01
Endereço303A College Road East
CidadePRINCETON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08540
Telefone18002083343
Sitehttps://www.pdsbiotech.com
Código da empresaPDSB
Data de listagemOct 01, 2015
CEOBedu-Addo (Frank)
Executivos da empresa PDS Biotechnology Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Interim Principal Financial Officer, Director
President, Chief Executive Officer, Interim Principal Financial Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Gregory L. Conn, Ph.D.
Dr. Gregory L. Conn, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Janetta Trochimiuk
Ms. Janetta Trochimiuk
Interim Principal Accounting Officer
Interim Principal Accounting Officer
--
--
Dr. Ilian Petkov Iliev, Ph.D.
Dr. Ilian Petkov Iliev, Ph.D.
Independent Director
Independent Director
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, General Counsel, Corporate Secretary and Compliance Officer
Senior Vice President, General Counsel, Corporate Secretary and Compliance Officer
--
--
Mr. Lars Boesgaard
Mr. Lars Boesgaard
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Interim Principal Financial Officer, Director
President, Chief Executive Officer, Interim Principal Financial Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Gregory L. Conn, Ph.D.
Dr. Gregory L. Conn, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Janetta Trochimiuk
Ms. Janetta Trochimiuk
Interim Principal Accounting Officer
Interim Principal Accounting Officer
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de PDS Biotechnology Corp?
Os cinco principais acionistas de PDS Biotechnology Corp são: Dr. Frank Bedu-Addo, Ph.D.
Quantas instituições possuem ações da PDS Biotechnology Corp (PDSB)?
Em 2026Q1, 167 instituições possuíam ações da PDS Biotechnology Corp, com valor de mercado aproximado de 9.62M, representando 17.24% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 2078771.00.